Ai Drug Discovery

OpenAI acquires biotech AI startup Orchestra Bio

OpenAI announced Tuesday it has acquired Orchestra Bio, a four-year-old startup that builds AI agents to help biotech firms manage drug discovery operations, including finances and clinical trial scheduling. Deal terms were not disclosed, though Orchestra had reportedly raised about $20 million from investors including Andreessen Horowitz, Atria, and 8VC. OpenAI plans to fold Orchestra's team and technology into Rosalind, its life sciences AI model, and the Rosalind Workbench tool used by customers such as Moderna and Novo Nordisk.

techcrunch.com · 2026-10-20

AstraZeneca signs up to $1.5B AI drug discovery deal with Insitro

AstraZeneca has agreed to pay AI-driven biotech company Insitro $40 million upfront, with potential milestone payments bringing the total deal value to as much as $1.46 billion. The partnership centers on using Insitro's machine learning platform for drug discovery.

wsj.com · 2026-10-15

Enveda raises $311M Series E at $2B valuation for AI-driven natural drug discovery

Enveda, a biotech startup using AI to identify drugs from plants and microbes, closed a $311 million Series E funding round at a $2 billion valuation. Catalio Capital Management led the round, with Iconiq and other investors participating. The valuation doubles what the company achieved a year earlier.

techcrunch.com · 2026-09-23